Upload
Featured Recent Articles Topics Login Upload

Search Results for 'Ibrutinib'

Ibrutinib published presentations and documents on DocSlides.

Ibrutinib: Analysis of Pivotal Data
Ibrutinib: Analysis of Pivotal Data
by alida-meadow
Richard R. Furman, MD. CLL Research Center. BCR-a...
Ibrutinib for Hairy Cell Leukemia
Ibrutinib for Hairy Cell Leukemia
by pasty-toler
. A Brief Update of an Ongoing Trial. Jeff Jones...
Ibrutinib : First-in Class Inhibitor of BTK
Ibrutinib : First-in Class Inhibitor of BTK
by briana-ranney
Forms a specific and irreversible bond with cyste...
Chronic lymphocytic leukemia,
Chronic lymphocytic leukemia,
by natalia-silvester
New agents timing?. Agne Paner, MD. Assistant pro...
Mechanisms of
Mechanisms of
by giovanna-bartolotta
Ibrutinib. Sensitivity and Resistance in CLL. Y....
Randomized Phase III
Randomized Phase III
by marina-yarberry
RESONATE . (PCYC-1112) Trial of Ibrutinib Compare...
BTK Inhibitors and Cardiac Considerations in Chronic Lymphocytic Leukemia
BTK Inhibitors and Cardiac Considerations in Chronic Lymphocytic Leukemia
by tawny-fly
Overview. Overview (cont). Ibrutinib. -R. elated ...
Btk inhibition in Mantle cell Lymphoma & CLL
Btk inhibition in Mantle cell Lymphoma & CLL
by test
Simon Rule. Professor of Clinical . Haematology. ...
Pharmacist Focus on BTK Inhibitors Moderator Shilpa Paul, PharmD, BCOP
Pharmacist Focus on BTK Inhibitors Moderator Shilpa Paul, PharmD, BCOP
by ellena-manuel
Pharmacist Focus on BTK Inhibitors Moderator Shil...
2022 Spring Oncology Conference
2022 Spring Oncology Conference
by byrne
Evolving Treatment Strategies. for CLL/SLL and MCL...
Module 3: Chronic Lymphocytic Leukemia
Module 3: Chronic Lymphocytic Leukemia
by CottonTails
Josie . Montegaard. , MSN, AGPCNP-BC. Matthew S . ...
CLL: clinical cases Celso Arrais
CLL: clinical cases Celso Arrais
by genevieve
Conflict of Interests. I declare NO relevant confl...
Randomized Comparison of Ibrutinib Versus Ofatumumab in Rel
Randomized Comparison of Ibrutinib Versus Ofatumumab in Rel
by jane-oiler
Presented By John Byrd at 2014 ASCO Annual Meetin...
Mantelcell
Mantelcell
by tawny-fly
. lymfom. Från. indolent till aggressive . sju...
Integration of Novel Therapies in WM and CLL : When and How
Integration of Novel Therapies in WM and CLL : When and How
by giovanna-bartolotta
Neil E Kay, M.D.. October 2014. Mayo Team. Deb Bo...
Updates in Lymphoma From Recent Congresses
Updates in Lymphoma From Recent Congresses
by lindy-dunigan
Therapeutic Targets in CLL. Venetoclax in Patient...
CLL Stromal cell protect
CLL Stromal cell protect
by tawny-fly
CLL Stromal cell protect Conventional therapies V...
Overall Survival Benefit of
Overall Survival Benefit of
by tatyana-admore
Obinutuzumab. Over Rituximab when Combined with ...
First Prospective Data on Minimal Residual Disease (MRD) Outcomes After Fixed-Duration Ibrutinib P
First Prospective Data on Minimal Residual Disease (MRD) Outcomes After Fixed-Duration Ibrutinib P
by mia
Ibr+Ven. ) Versus Chlorambucil Plus Obinutuzumab (...
uidelines
uidelines
by stella
Pan - London Haemato - O ncology Clinical G Lymph...
Research To Practice ASH 2022 CLL Updates
Research To Practice ASH 2022 CLL Updates
by erica
John N. Allan. Associate Professor of Clinical Med...
Prevalence of BTK and
Prevalence of BTK and
by kareem342
PLCG2. Mutations in CLL Patients relapsing under ...